Search Results for: ips cells

This morning here at The World Stem Cell Summit there was a healthy, frank discussion of the risks associated with receiving unlicensed, unproven stem cell therapies. Dr. Jim Guest presented first and gave a great talk about the risks associated with stem cell treatments. One such risk that was mentioned is inadequate characterization of stem …

Frank panel on hidden dangers of stem cell treatments to patients at WSCS2012 Read More »

There’s a new paper out this week in Cell from the Zaret lab that is very exciting. In this manuscript, Facilitators and Impediments of the Pluripotency Reprogramming Factors’ Initial Engagement with the Genome, Zaret’s team explores how Myc and Oct4, Sox2, and Klf4 (OSK) behave at the genomic level during cellular reprogramming. What are the most …

Review of the new Zaret Cell paper on Myc & OSK in cellular reprogramming Read More »

Much earlier this year I did a poll and published my own thoughts on the top 10 stem cell journals. Topping my list was Cell Stem Cell at #1 and Stem Cells at #2. I also recently did text mining on the titles of articles in these 2 journals (here and here) finding some fascinating similarities …

Top Stem Cell Journals list for 2013: some surprises Read More »

When biotech Geron punted on its embryonic stem cell (ESC) program despite having an ongoing FDA-approved clinical trial for spinal cord injury and tens of millions in loan funding from CIRM, many in the stem cell field were upset to put it mildly. Geron repaid the CIRM loan with interest. At the time, the general …

CIRM comment on prospect of BioTime buying Geron stem cell program Read More »

I’m doing a series of posts on straightforward reasons why patients should not get unlicensed stem cell treatments. Part 1 of the series was on the risk of losing medical insurance coverage. Today is part 2, which is focused on a serious failing of many for-profit, point-of-care stem cell clinics selling unlicensed treatments: lack of …

8 simple reasons not to get an unlicensed stem cell treatment part 2: lack of follow-up Read More »

Pluristem Therapeutics Inc. is a publicly traded (NASDAQ) biotech Israeli company that is developing stem cell treatments based on the use of expanded placental stem cells called PLX cells. The Pluristem PLX drug is not approved for treating patients at this time in any country, however Pluristem has treated a handful of patients via something …

Money and stem cell ‘miracles’: Pluristem questioned on ethics Read More »

Cell Stem Cell was the winner of my 2011 best stem cell journal award (see 2011 awards here, 2012 awards will be announced in early January). As I’ve “complained” in the past, the only thing I wish would be different is they’d publish even more articles per issue or per month! But what exactly does Cell …

Text mining Cell Stem Cell: surprising insights into the journal Read More »

The odds of Mitt Romney becoming our next President seem to be increasing. If Romney becomes our next president, what will he do about stem cells? He’ll be an active enemy of embryonic stem cell research. He’ll support the crazy personhood movement. Why do I say that? Earlier this year I had a run in …

If Romney wins, look for extremist Witherspoon Council to control his stem cell policy Read More »